Abstract
Background White matter hyperintensities (WMHs) are pathological changes that develop with increased age and are associated with cognitive decline. Most research on WMHs has neglected to examine regional differences and instead focuses on using a whole-brain approach. This study examined regional WMH differences between normal controls (NCs), people with mild cognitive impairment (MCI), and Alzheimer’s disease (AD). Another goal was to examine whether WMH burden was associated with declines in different cognitive domains in each of the groups.
Methods Participants were selected from the Alzheimer’s Disease Neuroimaging Initiative and included if they had at least one WMH measurement and cognitive scores examining global cognition, executive functioning, and memory. MCI and AD participants were included only if they were amyloid positive. A total of 1573 participants with 7381 follow-ups met inclusion criteria. Linear mixed-effects models were completed to examine group differences in WMH burden and the association between WMH burden and cognition in aging, MCI, and AD.
Results People with MCI and AD had increased total and regional WMH burden compared to cognitively healthy older adults. An association between WMH and cognition was observed for global cognition, executive functioning, and memory in NCs in all regions of interest. A steeper decline (stronger association between WMH and cognition) was observed in MCI compared to NCs for all cognitive domains in all regions. A steeper decline was observed in AD compared to NCs for global cognition in only the temporal region.
Conclusion These results suggest WMH burden increases from aging to AD. A strong association is observed between all cognitive domains of interest and WMH burden in healthy aging and MCI, while those with AD only had a few associations between WMH and memory and WMH and global cognition. These findings suggest that WMH burden is associated with changes in cognition in healthy aging and early cognitive decline, but other biological changes may have a stronger impact on cognition with AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data was accessed and downloaded from the ADNI public website. A written request was submitted and approved to receive access to the data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Statements and Declarations
Funding information Dr. Dadar reports receiving research funding from the Healthy Brains for Healthy Lives (HBHL), Alzheimer Society Research Program (ASRP), and Douglas Research Centre (DRC).
Conflict of Interest The authors declare no competing interests
Data Availability
All data used in this article are available from the ADNI public database upon written request for the data.
